↓ Skip to main content

Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1‐FV in a randomized controlled trial

Overview of attention for article published in Clinical and Translational Allergy, August 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)

Mentioned by

twitter
3 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1‐FV in a randomized controlled trial
Published in
Clinical and Translational Allergy, August 2015
DOI 10.1186/s13601-015-0071-x
Pubmed ID
Authors

Ludger Klimek, Claus Bachert, Karl‐Friedrich Lukat, Oliver Pfaar, Hanns Meyer, Annemie Narkus

Abstract

Pollen extracts and chemically modified allergoids are used successfully in allergen immunotherapy (AIT). Recombinant extracts offer potential advantages with respect to pharmaceutical quality, standardization and dosing. A hypoallergenic recombinant folding variant of the major birch pollen allergen (rBet v 1-FV) was compared with an established native birch preparation. A pre-seasonal, randomized, actively controlled phase II study was performed in birch pollen allergic rhino-conjunctivitis with or without asthma, GINA I/ II. 51 patients (24 rBet v 1-FV, 27 native extract) started therapy with subcutaneous allergen immunotherapy (SCIT). Primary end-point was a combined symptom medication score (SMS), changes in nasal provocation test, visual rating score and specific antibody responses secondary end-points. After one pre-seasonal treatment course the combined SMS was 5.86 (median; IQR: 14.02) for the rBet v 1-FV group versus 12.40 (median; IQR: 9.32) for the comparator during the three weeks pollen season (p = 0.330). After treatment in the second year, scores were 3.00 (median; IQR: 6.50) and 2.93 (4.86) respectively. Allergen tolerance in a nasal provocation test improved to a comparable extent in both groups. Significant increases in birch pollen-specific IgG1 and IgG4 were observed in both treatment groups following the first treatment phase and remained significantly raised until the end of the study. In this first in man, proof of concept phase II trial no statistical difference between rBet v 1-FV and an established natural pollen extract could be observed. rBet v 1-FV could be administered in higher doses than the native protein with no increase in adverse effects. The study was registered in clinicalTrials.gov (NCT00266526).

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Finland 1 2%
Unknown 42 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 19%
Student > Master 7 16%
Other 6 14%
Student > Bachelor 6 14%
Researcher 5 12%
Other 3 7%
Unknown 8 19%
Readers by discipline Count As %
Medicine and Dentistry 9 21%
Biochemistry, Genetics and Molecular Biology 8 19%
Immunology and Microbiology 6 14%
Agricultural and Biological Sciences 5 12%
Chemistry 2 5%
Other 3 7%
Unknown 10 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2016.
All research outputs
#9,547,846
of 17,039,068 outputs
Outputs from Clinical and Translational Allergy
#357
of 508 outputs
Outputs of similar age
#102,667
of 240,313 outputs
Outputs of similar age from Clinical and Translational Allergy
#1
of 1 outputs
Altmetric has tracked 17,039,068 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 508 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,313 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them